← Analysis page  ·  Pieter Slegers hub  ·  Research hub

Actionable insights — I'm Buying The Whole Business

How to value a control purchase rather than a share purchase: recoup-period arithmetic, the two multiple framings and why they disagree, float as costless leverage, and the stress test that decides whether any of it survives.
2026-SEP-08 · Compounding Quality (Substack, paid post) · Pieter Slegers · read ↗ · full analysis · transcript
How to read this page: insights 1-5 are the method the issue actually teaches, and they are reusable on any small, cash-generative business — the recoup-period frame, the two multiple framings, the float test, the stress input, and the "cheap enough that a bad business still pays" test taken from Buffett's own worst trade. Insights 6-7 are the checks the letter omits and that anyone re-running this model should add before believing an output. Written post, so there are no timestamps; each insight cites the section of the article it comes from.

1. Value a whole-business purchase by its recoup period, not by its multiple

The repeatable method
  1. Take the business's annual free cash flow and divide the purchase price by it. That number is the recoup period in years — the multiple restated as time.
  2. Assume the business merely survives and grows with inflation. Do not model improvement.
  3. From the recoup year onwards, treat the full annual cash flow as new investable capital, deployed at your normal market return.
  4. Compare that path against putting the same equity into the market on day one and leaving it there.
  5. Judge the deal on the gap between the two paths over your actual holding period, not on the entry multiple in isolation.
Here: a "very stable boring company" generating $1m of free cash flow bought for $5m — "you will recoup your entire investment in 5 years… from year 6, you will have an extra million to invest every single year." Over 25 years: $54.2m from just investing at 10% versus $171.0m from buying the business. "It's the difference between compounding at 10% per year versus compounding at 20% per year."
Watch for

2. Run the deal twice — once on EBITDA, once on earnings — and let the gap tell you how much is leverage

The repeatable method
  1. Frame one: enterprise value = EBITDA × entry multiple. This is what the whole business costs including its debt, before interest and tax.
  2. Frame two: price = net earnings × P/E. This is what the equity costs, after interest and tax.
  3. Run the identical assumptions through both and record the 20-year value, the CAGR and the equity actually invested.
  4. Compare the two answers. A wide gap is not noise — it is the size of the benefit your model is attributing to the capital structure and the tax shield.
  5. Report both; publishing only the flattering framing is the tell.
Here, on SNFCA: EBITDA framing at 3.3x → EUR 4.22bn versus EUR 606m, a 6.96x edge and 21.2% CAGR on EUR 90.09m of equity. P/E framing at 6.5x → EUR 2.46bn versus EUR 704m, a 3.49x edge and 17.1% CAGR on EUR 104.65m of equity. The explanation given is only "the multiple you pay differs."
Watch for

3. Test whether an insurance business gives you float you can actually invest

The repeatable method
  1. Establish the gap between premium collection and claim payment — the longer and more predictable, the more usable the float.
  2. Check underwriting profitability. Float is only free if the insurance itself at least breaks even; an underwriting loss is the interest rate on that borrowing.
  3. Size the float against the equity you are putting up. That ratio is your true leverage, and it does not appear on any multiple.
  4. Ask what the float may be invested in — reserve rules, duration matching and regulator constraints decide whether "invest it in equities" is available at all.
  5. Only then add the float's investment return to the deal's expected return.
Here: the beginner's version — a $1,500 annual car premium against an average claim of $8,000-$10,000 once every 17-18 years. Berkshire's float: ~$26bn (2000) → ~$113bn (2019) → ~$175bn (4Q 2025). The structural claim: "If Berkshire Hathaway would use it's operating profit and float to just copy the S&P 500, by definition it will outperform the index because they have 'free money' to invest in the index."
Watch for

4. Put the disaster in the model as an input, not as a caveat

The repeatable method
  1. Add three explicit fields: the year the bad thing happens, the multiplier applied to earnings/EBITDA that year, and the interest rate you refinance at afterwards.
  2. Set the shock mid-hold, where debt is still outstanding and compounding has not yet done its work — that is the vulnerable window.
  3. Refinance at a punitive rate from the shock year onward, not just for one year.
  4. Re-run and check that the deal still clears the do-nothing alternative. If it only works shock-free, the leverage is too high.
  5. Report the shocked figure as the headline, not the clean one.
Here: the assumptions tab carries a live stress scenario — shock on, year 7, earnings/EBITDA multiplier 50%, interest rate after shock 9% (against 5% before) — and the published results survive it. That is the strongest fact in the issue, and the prose never mentions it.
Watch for

5. Use the "cheap enough that a bad business still pays" test

The repeatable method
  1. Value the assets you would own outright — working capital, cash, receivables, inventories — per share.
  2. Express the price you would pay as a fraction of that. Below ~0.5x, the asset base alone is a floor.
  3. Then, separately, forecast nothing: sum what the operating business plausibly generates over the next decade even in decline.
  4. Ask whether the second number alone exceeds the price. If it does, the business quality is a bonus rather than the thesis.
  5. Recognise the trade-off explicitly — this buys you protection, not compounding; you still need somewhere to redeploy the cash.
Here: Buffett's Berkshire entry, reconstructed — price paid $14.86, value of assets $32.30, multiple paid 0.46, working capital alone $19 a share. Over 1965-1974 the dying textile mill produced $418.5m of revenue and $20.7m of operating profit — $20.3 per share against $14.86 paid. "It's definitely not the best investment in the world, but it's also not terrible."
Watch for

6. Before believing any of it, price the thing the model leaves out: control

The repeatable method
  1. Establish whether a controlling stake is actually purchasable — founder and insider holdings, dual-class shares, and any poison pill.
  2. Add the control premium to the entry multiple. A quoted 6.5x P/E is a minority price; a control price is typically materially higher.
  3. Add transaction costs, financing fees and the time cost of a contested process.
  4. Re-run the model at the control price, not the screen price. If the edge disappears, the deal was an artefact of the quote.
  5. Ask separately whether you can run the business, and who does if you cannot.
Here: the model is fed SNFCA's market statistics — 0.6x book, 3.3x EV/EBITDA, 6.5x P/E, 3.1x P/FCF — with the phrase "Let's just say that we could acquire the company for 5x it's cash flow." No control premium, no shareholder register, no discussion of availability. The reader is asked to accept the screen price as the acquisition price.
Watch for

7. Keep your quality gate in front of the arithmetic, not behind it

The repeatable method
  1. Run the qualitative screen first — moat, returns on capital, durability of cash flow, management — exactly as you would for a share purchase.
  2. Only then compute the acquisition arithmetic. A model applied to a business that fails the gate produces a precise wrong answer.
  3. Compare the levered whole-business case against a levered market alternative, not an unlevered one, so the debt is not credited to the strategy.
  4. Show a sensitivity on the debt share — 0%, 50%, 80% — since the assumptions tab itself labels 80% "max leverage."
  5. Re-read your own most recent stated rule before making an exception to it.
Here: the sequence runs the other way — cheapness first ("And it's cheap:"), quality never. That is precisely the pattern confessed one week earlier in Part I: "Almost every time I made a buy decision because I thought the company was somewhat quality but definitely cheap, it was a mistake in hindsight." And every headline figure is levered 50/50 at 5% with deductible interest, while "just investing" is unlevered.
Watch for

Methods distilled from the archived Compounding Quality post (text and transcribed tables in transcript.txt). Not investment advice.